

ATHEROGENICS INC  
Form 15-12G  
June 22, 2009

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
FORM 15**

**Certification and Notice of Termination of Registration under Section 12(g) of the Securities Exchange Act of 1934 or Suspension of Duty to File Reports Under Sections 13 and 15(d) of the Securities Exchange Act of 1934.  
Commission File Number: 0-31261  
AtheroGenics, Inc.**

(Exact name of registrant as specified in its charter)  
8995 Westside Parkway  
Alpharetta, Georgia 30009  
(678) 336-2500

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)  
Common Stock, No Par Value  
Common Stock Purchase Rights  
4.5% Convertible Notes due 2008  
1.5% Convertible Notes due 2012

(Title of each class of securities covered by this Form)  
N/A

(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)	<input checked="" type="checkbox"/>
Rule 12g-4(a)(2)	<input type="checkbox"/>
Rule 12h-3(b)(1)(i)	<input checked="" type="checkbox"/>
Rule 12h-3(b)(1)(ii)	<input type="checkbox"/>
Rule 15d-6	<input type="checkbox"/>

Approximate number of holders of record as of the certification or notice date:

Common Stock, No Par Value: 1  
Common Stock Purchase Rights: 1  
4.5% Convertible Notes due 2008: 0  
1.5% Convertible Notes due 2012: 0

Edgar Filing: ATHEROGENICS INC - Form 15-12G

Pursuant to the requirements of the Securities Exchange Act of 1934, AtheroGenics, Inc. has caused this Certification and Notice to be signed on its behalf by the undersigned duly authorized person.

ATHEROGENICS, INC.

Date: June 22, 2009

By: /s/ Charles A. Deignan  
Charles A. Deignan  
President, Chief Financial Officer and  
Secretary